Bild: Germany readies for coronavirus vaccine before end of year

Coronavirus vaccine

At the time, Brazil's President Jair Bolsonaro, who himself has recovered from COVID-19, said the money was meant to invest in research and purchase "a batch of vaccines for us".

"Moderna is committed to rigorous scientific research and the highest data quality standards".

According to the National Health Commission, China's total annual production capacity of COVID-19 vaccines will likely reach 610 million doses by the end of the year and continue to expand next year to meet the demand for COVID-19 vaccines in China and other countries.

There is a chance they will have more than one vaccine. "If we do it wrong, then we're done for".

The company could apply to the FDA for authorization of use to start in early December, barring any complications. That confidence will be critical to efforts to vaccinate millions of Americans.

"If we have a low efficacy vaccine where a certain proportion of people who get the vaccine will not be protected against the disease, that would be a whole different calculation", he says. While he's encouraged by Pfizer's study in adolescents, he finds it "very concerning" that children younger than 12 may not have a vaccine by next fall.

According to them, the Centre will procure the vaccine directly to make it available to the priority groups free-of-charge through the existing network of states and districts.

Thursday's meeting wasn't to evaluate any particular shots. Some vaccines produced in Russian Federation and China have already been approved for early or limited use in their respective nations, but none have completed Phase 3 trials yet.

The panelists were divided over whether two months is enough - some wanted six.

A clinical trial of the vaccine in the USA has been on hold for more than a month.

The figure includes more than 6,000 Hispanic participants and 3,000 African Americans, VOA reported.

The researchers examined multiple factors linked to the acceptance of a Covid-19 vaccine, with one of the key factors in the level of vaccine acceptance being the study participants' beliefs about the origin of the virus.

The Hyderabad-based vaccine maker had applied to the Drugs Controller General of India (DCGI) on October 2, seeking its permission to conduct Phase 3 trials for its COVID-19 vaccine candidate. "We are finding these cases and working them up thoroughly".

J&J, in its comments, said a discussion is needed on the potential challenges of maintaining trial enrollment in ongoing large studies, especially after initial vaccines become available.

The person asked not to be identified because the information isn't public.

It's an unprecedented dilemma. So the government is planning extra scrutiny of every COVID-19 vaccine to hit the market.

FDA also will be checking databases of electronic health records and insurance claims, looking for any red flags.